Search

Your search keyword '"Efstathiou, Jason A."' showing total 43 results
Start Over Author "Efstathiou, Jason A." Journal international journal of radiation oncology, biology, physics
43 results on '"Efstathiou, Jason A."'

1. Long-Term Results of Bladder Preservation With Twice-Daily Radiation Plus 5-Fluorouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer—Updated Report of NRG/RTOG 0712: A Randomized Phase 2 Trial

Author

Coen, John J., Rodgers, Joseph P., Saylor, Philip J., Lee, Cheryl T., Wu, Chin-Lee, Parker, William, Lautenschlaeger, Tim, Zietman, Anthony L., Efstathiou, Jason, Jani, Ashesh B., Kucuk, Omer, Souhami, Luis, Pugh, Stephanie L., Sandler, Howard M., and Shipley, William U.

Published
2024
Full Text
View/download PDF

2. Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial

Author

Spratt, Daniel E., Liu, Vinnie Y.T., Michalski, Jeff, Davicioni, Elai, Berlin, Alejandro, Simko, Jeffry P., Efstathiou, Jason A., Tran, Phuoc T., Sandler, Howard M., Hall, William A., Thompson, Darby J.S., Parliament, Matthew B., Dayes, Ian S., Correa, Rohann Jonathan Mark, Robertson, John M., Gore, Elizabeth M., Doncals, Desiree E., Vigneault, Eric, Souhami, Luis, Karrison, Theodore G., and Feng, Felix Y.

Published
2023
Full Text
View/download PDF

3. Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer

Author

Lukka, Himanshu R., Deshmukh, Snehal, Bruner, Deborah W., Bahary, Jean-Paul, Lawton, Colleen A.F., Efstathiou, Jason A., Kudchadker, Rajat J., Ponsky, Lee E., Seaward, Samantha A., Dayes, Ian S., Gopaul, Darindra D., Michalski, Jeff M., Delouya, Guila, Kaplan, Irving D., Horwitz, Eric M., Roach, Mack, III, Feng, Felix Y., Pugh, Stephanie L., Sandler, Howard M., and Kachnic, Lisa A.

Published
2023
Full Text
View/download PDF

4. Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials

Author

Nguyen, Paul L., Huang, Huei-Chung (Rebecca), Spratt, Daniel E., Davicioni, Elai, Sandler, Howard M., Shipley, William U., Efstathiou, Jason A., Simko, Jeffry P., Pollack, Alan, Dicker, Adam P., Roach, Mack, Rosenthal, Seth A., Zeitzer, Kenneth L., Mendez, Lucas C., Hartford, Alan C., Hall, William A., Desai, Anand B., Rabinovitch, Rachel A., Peters, Christopher A., Rodgers, Joseph P., Tran, Phuoc, and Feng, Felix Y.

Published
2023
Full Text
View/download PDF

5. Neighborhood Deprivation and Rurality Associated With Patient-Reported Outcomes and Survival in Men With Prostate Cancer in NRG Oncology RTOG 0415

Author

Bai, Jinbing, Pugh, Stephanie L., Eldridge, Ronald, Yeager, Katherine A., Zhang, Qi, Lee, W. Robert, Shah, Amit B., Dayes, Ian S., D'Souza, David P., Michalski, Jeff M., Efstathiou, Jason A., Longo, John M., Pisansky, Thomas M., Maier, Jordan M., Faria, Sergio L., Desai, Anand B., Seaward, Samantha A., Sandler, Howard M., Cooley, Mary E., and Bruner, Deborah W.

Published
2023
Full Text
View/download PDF

7. Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial

Author

Jones, Christopher U., Pugh, Stephanie L., Sandler, Howard M., Chetner, Michael P., Amin, Mahul B., Bruner, Deborah W., Zietman, Anthony L., Den, Robert B., Leibenhaut, Mark H., Longo, John M., Bahary, Jean-Paul, Rosenthal, Seth A., Souhami, Luis, Michalski, Jeff M., Hartford, Alan C., Amin, Pradip P., Roach, Mack, III, Yee, Don, Efstathiou, Jason A., Rodgers, Joseph P., Feng, Felix Y., and Shipley, William U.

Published
2022
Full Text
View/download PDF

8. Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer.

Author

Bryant, Alex K, Kader, Andrew K, McKay, Rana R, Einck, John P, Mell, Loren K, Mundt, Arno J, Kane, Christopher J, Efstathiou, Jason A, Murphy, James D, and Rose, Brent S

Subjects
Lymph Nodes, Humans, Prostatic Neoplasms, Neoplasm Metastasis, Lymphatic Metastasis, Androgen Antagonists, Prostate-Specific Antigen, Disease-Free Survival, Treatment Outcome, Incidence, Multivariate Analysis, Proportional Hazards Models, Cohort Studies, Time Factors, Databases, Factual, Aged, Middle Aged, Hospitals, Veterans, Male, Prostate Cancer, Patient Safety, Urologic Diseases, Aging, Cancer, Good Health and Well Being, Other Physical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeThe survival benefit of combined radiation therapy (RT) and androgen deprivation therapy (ADT) compared with ADT alone for clinically lymph node-positive prostate cancer remains controversial.Methods and materialsWe identified patients with clinically node-positive, nonmetastatic prostate cancer diagnosed between 2000 and 2015 and treated with ADT (n = 450) or ADT-RT (n = 198) from a national Veterans Affairs database. We compared prostate cancer-specific mortality (PCSM) and all-cause mortality (ACM) between treatment groups using multivariable competing-risks regression and Cox regression, respectively. An interaction term between ADT-RT and prostate-specific antigen (PSA) level (dichotomized about the median) was included in the multivariable models.ResultsADT-RT was associated with improved PCSM among patients with PSA levels less than the median of 26 ng/mL (sub-distribution hazard ratio, 0.50; 95% confidence interval [CI] 0.28-0.88; P = .02) but not greater than the median (hazard ratio [HR], 1.15; 95% CI 0.67-1.96; P = .62) (P = .038 for interaction). ADT-RT was also associated with improved ACM among patients with PSA levels less than the median (HR, 0.38; 95% CI 0.25-0.57; P

Published
2018

9. NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer

Author

Hall, William A., Paulson, Eric, Davis, Brian J., Spratt, Daniel E., Morgan, Todd M., Dearnaley, David, Tree, Alison C., Efstathiou, Jason A., Harisinghani, Mukesh, Jani, Ashesh B., Buyyounouski, Mark K., Pisansky, Thomas M., Tran, Phuoc T., Karnes, R. Jeffrey, Chen, Ronald C., Cury, Fabio L., Michalski, Jeff M., Rosenthal, Seth A., Koontz, Bridget F., Wong, Anthony C., Nguyen, Paul L., Hope, Thomas A., Feng, Felix, Sandler, Howard M., and Lawton, Colleen A.F.

Published
2021
Full Text
View/download PDF

10. Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop.

Author

Smith, Grace L, Ganz, Patricia A, Bekelman, Justin E, Chmura, Steven J, Dignam, James J, Efstathiou, Jason A, Jagsi, Reshma, Johnstone, Peter A, Steinberg, Michael L, Williams, Stephen B, Yu, James B, Zietman, Anthony L, Weichselbaum, Ralph R, and Tina Shih, Ya-Chen

Subjects
Humans, Neoplasms, Radiotherapy, Program Evaluation, Technology, Radiologic, Decision Making, Radiation Oncology, Diffusion of Innovation, Research Personnel, Costs and Cost Analysis, United States, Radiotherapy, Intensity-Modulated, Proton Therapy, National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division, Cancer, Comparative Effectiveness Research, Quality Education, Other Physical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeLeaders in the oncology community are sounding a clarion call to promote "value" in cancer care decisions. Value in cancer care considers the clinical effectiveness, along with the costs, when selecting a treatment. To discuss possible solutions to the current obstacles to achieving value in the use of advanced technologies in oncology, the National Cancer Policy Forum of the National Academies of Sciences, Engineering, and Medicine held a workshop, "Appropriate Use of Advanced Technologies for Radiation Therapy and Surgery in Oncology" in July 2015. The present report summarizes the discussions related to radiation oncology.Methods and materialsThe workshop convened stakeholders, including oncologists, researchers, payers, policymakers, and patients. Speakers presented on key themes, including the rationale for a value discussion on advanced technology use in radiation oncology, the generation of scientific evidence for value of advanced radiation technologies, the effect of both scientific evidence and "marketplace" (or economic) factors on the adoption of technologies, and newer approaches to improving value in the practice of radiation oncology. The presentations were followed by a panel discussion with dialogue among the stakeholders.ResultsChallenges to generating evidence for the value of advanced technologies include obtaining contemporary, prospective, randomized, and representative comparative effectiveness data. Proposed solutions include the use of prospective registry data; integrating radiation oncology treatment, outcomes, and quality benchmark data; and encouraging insurance coverage with evidence development. Challenges to improving value in practice include the slow adoption of higher value and the de-adoption of lower value treatments. The proposed solutions focused on engaging stakeholders in iterative, collaborative, and evidence-based efforts to define value and promote change in radiation oncology practice. Recent examples of ongoing or successful responses to the discussed challenges were provided.ConclusionsDiscussions of "value" have increased as a priority in the radiation oncology community. Practitioners in the radiation oncology community can play a critical role in promoting a value-oriented framework to approach radiation oncology treatment.

Published
2017

12. Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer

Author

Lukka, Himanshu R., Pugh, Stephanie L., Bruner, Deborah W., Bahary, Jean-Paul, Lawton, Colleen A.F., Efstathiou, Jason A., Kudchadker, Rajat J., Ponsky, Lee E., Seaward, Samantha A., Dayes, Ian S., Gopaul, Darindra D., Michalski, Jeff M., Delouya, Guila, Kaplan, Irving D., Horwitz, Eric M., Roach, Mack, III, Pinover, Wayne H., Beyer, David C., Amanie, John O., Sandler, Howard M., and Kachnic, Lisa A.

Published
2018
Full Text
View/download PDF

14. Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy—A Multi-Institutional Observational Study

Author

Pisansky, Thomas M., Agrawal, Shree, Hamstra, Daniel A., Koontz, Bridget F., Liauw, Stanley L., Efstathiou, Jason A., Michalski, Jeff M., Feng, Felix Y., Abramowitz, Matthew C., Pollack, Alan, Anscher, Mitchell S., Moghanaki, Drew, Den, Robert B., Stephans, Kevin L., Zietman, Anthony L., Lee, W. Robert, Kattan, Michael W., Stephenson, Andrew J., and Tendulkar, Rahul D.

Published
2016
Full Text
View/download PDF

17. Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy

Author

Baumann, Brian C., Bosch, Walter R., Bahl, Amit, Birtle, Alison J., Breau, Rodney H., Challapalli, Amarnath, Chang, Albert J., Choudhury, Ananya, Daneshmand, Sia, El-Gayed, Ali, Feldman, Adam, Finkelstein, Steven E., Guzzo, Thomas J., Hilman, Serena, Jani, Ashesh, Malkowicz, S. Bruce, Mantz, Constantine A., Master, Viraj, Mitra, Anita V., Murthy, Vedang, Porten, Sima P., Richaud, Pierre M., Sargos, Paul, Efstathiou, Jason A., Eapen, Libni J., and Christodouleas, John P.

Published
2016
Full Text
View/download PDF

22. Addressing the Growing Cancer Burden in the Wake of the AIDS Epidemic in Botswana: The BOTSOGO Collaborative Partnership

Author

Efstathiou, Jason A., Bvochora-Nsingo, Memory, Gierga, David P., Alphonse Kayembe, Mukendi K., Mmalane, Mompati, Russell, Anthony H., Paly, Jonathan J., Brown, Carolyn, Musimar, Zola, Abramson, Jeremy S., Bruce, Kathy A., Karumekayi, Talkmore, Clayman, Rebecca, Hodgeman, Ryan, Kasese, Joseph, Makufa, Remigio, Bigger, Elizabeth, Suneja, Gita, Busse, Paul M., Randall, Thomas C., Chabner, Bruce A., and Dryden-Peterson, Scott

Published
2014
Full Text
View/download PDF

24. Outcomes in a Multi-institutional Cohort of Patients Treated With Intraoperative Radiation Therapy for Advanced or Recurrent Renal Cell Carcinoma

Author

Paly, Jonathan J., Hallemeier, Christopher L., Biggs, Peter J., Niemierko, Andrzej, Roeder, Falk, Martínez-Monge, Rafael, Whitson, Jared, Calvo, Felipe A., Fastner, Gerd, Sedlmayer, Felix, Wong, William W., Ellis, Rodney J., Haddock, Michael G., Choo, Richard, Shipley, William U., Zietman, Anthony L., and Efstathiou, Jason A.

Published
2014
Full Text
View/download PDF

28. Redesigning Radiotherapy Quality Assurance: Opportunities to Develop an Efficient, Evidence-Based System to Support Clinical Trials—Report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance

Author

Bekelman, Justin E., Deye, James A., Vikram, Bhadrasain, Bentzen, Soren M., Bruner, Deborah, Curran, Walter J., Jr., Dignam, James, Efstathiou, Jason A., FitzGerald, T.J., Hurkmans, Coen, Ibbott, Geoffrey S., Lee, J. Jack, Merchant, Thomas E., Michalski, Jeff, Palta, Jatinder R., Simon, Richard, Ten Haken, Randal K., Timmerman, Robert, Tunis, Sean, Coleman, C. Norman, and Purdy, James

Published
2012
Full Text
View/download PDF

29. Prospective Preference Assessment of Patients' Willingness to Participate in a Randomized Controlled Trial of Intensity-Modulated Radiotherapy Versus Proton Therapy for Localized Prostate Cancer

Author

Shah, Anand, Efstathiou, Jason A., Paly, Jonathan J., Halpern, Scott D., Bruner, Deborah W., Christodouleas, John P., Coen, John J., Deville, Curtiland, Jr., Vapiwala, Neha, Shipley, William U., Zietman, Anthony L., Hahn, Stephen M., and Bekelman, Justin E.

Published
2012
Full Text
View/download PDF

38. Overview of the American Society for Radiation Oncology–National Institutes of Health–American Association of Physicists in Medicine Workshop 2015: Exploring Opportunities for Radiation Oncology in the Era of Big Data

Author

Benedict, Stanley H., Hoffman, Karen, Martel, Mary K., Abernethy, Amy P., Asher, Anthony L., Capala, Jacek, Chen, Ronald C., Chera, Bhisham, Couch, Jennifer, Deye, James, Efstathiou, Jason A., Ford, Eric, Fraass, Benedick A., Gabriel, Peter E., Huser, Vojtech, Kavanagh, Brian D., Khuntia, Deepak, Marks, Lawrence B., Mayo, Charles, McNutt, Todd, Miller, Robert S., Moore, Kevin L., Prior, Fred, Roelofs, Erik, Rosenstein, Barry S., Sloan, Jeff, Theriault, Anna, and Vikram, Bhadrasain

Published
2016
Full Text
View/download PDF

41. Closing the Cancer Divide Through Ubuntu: Information and Communication Technology-Powered Models for Global Radiation Oncology

Author

Ngwa, Wilfred, Ngoma, Twalib, Zietman, Anthony, Mayr, Nina, Elzawawy, Ahmed, Winningham, Thomas A., Balogun, Onyinye, Enwerem-Bromson, Nelly, Ntizimira, Christian, Olopade, Olufunmilayo I., Oluwole, Doyin, Odedina, Folakemi, Williams, Makeda, Flanigan, John, Asana, Lydia, Ngwa, Kenneth, Avery, Stephen, Pollard, Julianne M., Roland, Teboh, Funwi-gabga, Neba, Mbarika, Victor, Hardenbergh, Patricia, Winkfield, Karen, Pipman, Yakov, Stefan, Christina, Ngoma, Mamsau, Mohammed, Sulma, Katz, Matthew, Erno, Sajo, Moni, Janaki, Fitzgerald, Thomas, Tonlaar, Nathan, Efstathiou, Jason, Gierga, David, Ayo, Charles, Knaul, Felicia, Gospodarowicz, Mary, Makrigiorgos, G. Mike, and Nguyen, Paul L.

Published
2016
Full Text
View/download PDF

42. Body Mass Index and Prostate-Specific Antigen Failure Following Brachytherapy for Localized Prostate Cancer

Author

Efstathiou, Jason A., Skowronski, Rafi Y., Coen, John J., Grocela, Joseph A., Hirsch, Ariel E., and Zietman, Anthony L.

Subjects
*BODY mass index, *TUMOR growth, *PROSTATE cancer, *TUMOR antigens
Abstract

Purpose: Increasing body mass index (BMI) is associated with prostate-specific antigen (PSA) failure after radical prostatectomy and external beam radiation therapy (EBRT). We investigated whether BMI is associated with PSA failure in men treated with brachytherapy for clinically localized prostate cancer. Patients and Methods: Retrospective analyses were conducted on 374 patients undergoing brachytherapy for stage T1c–T2cNXM0 prostate cancer from 1996–2001. Forty-nine patients (13%) received supplemental EBRT and 131 (35%) received androgen deprivation therapy (ADT). Height and weight data were available for 353 (94%). Cox regression analyses were performed to evaluate the relationship between BMI and PSA failure (nadir + 2 ng/ml definition). Covariates included age, race, preimplantation PSA, Gleason score, T category, percent of prescription dose to 90% of the prostate, use of supplemental EBRT, and ADT. Results: Median age, PSA, and BMI were 66 years (range, 42–80 years), 5.7 ng/ml (range, 0.4–22.6 ng/ml), and 27.1 kg/m2 (range, 18.2–53.6 kg/m2), respectively. After a median follow-up of 6.0 years (range, 3.0–10.2 years), there were 76 PSA recurrences. The BMI was not associated with PSA failure. Six-year PSA failure rates were 30.2% for men with BMI less than 25 kg/m2, 19.5% for BMI of 25 or greater to less than 30 kg/m2, and 14.4% for BMI of 30 kg/m2 or greater (p = 0.19). Results were similar when BMI was analyzed as a continuous variable, using alternative definitions of PSA failure, and excluding patients treated with EBRT and/or ADT. In multivariate analyses, only baseline PSA was significantly associated with shorter time to PSA failure (adjusted hazard ratio, 1.12; 95% confidence interval, 1.05–1.20; p = 0.0006). Conclusions: Unlike after surgery or EBRT, BMI is not associated with PSA failure in men treated with brachytherapy for prostate cancer. This raises the possibility that brachytherapy may be a preferred treatment strategy in obese patients. [Copyright &y& Elsevier]

Published
2008
Full Text
View/download PDF

43. Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer.

Author

Einck, John P., Mundt, Arno J., Bryant, Alex K., Mell, Loren K., Murphy, James D., Rose, Brent S., Kader, Andrew K., Kane, Christopher J., McKay, Rana R., and Efstathiou, Jason A.

Subjects
*RADIOTHERAPY, *ANDROGENS, *PROSTATE cancer treatment, *REGRESSION analysis, *LYMPH nodes, *ANTIANDROGENS, *DATABASES, *LONGITUDINAL method, *METASTASIS, *MULTIVARIATE analysis, *PROGNOSIS, *PROSTATE tumors, *TIME, *VETERANS' hospitals, *PROSTATE-specific antigen, *TREATMENT effectiveness, *DISEASE incidence, *PROPORTIONAL hazards models, *THERAPEUTICS
Abstract

Purpose: The survival benefit of combined radiation therapy (RT) and androgen deprivation therapy (ADT) compared with ADT alone for clinically lymph node-positive prostate cancer remains controversial.Methods and Materials: We identified patients with clinically node-positive, nonmetastatic prostate cancer diagnosed between 2000 and 2015 and treated with ADT (n = 450) or ADT-RT (n = 198) from a national Veterans Affairs database. We compared prostate cancer-specific mortality (PCSM) and all-cause mortality (ACM) between treatment groups using multivariable competing-risks regression and Cox regression, respectively. An interaction term between ADT-RT and prostate-specific antigen (PSA) level (dichotomized about the median) was included in the multivariable models.Results: ADT-RT was associated with improved PCSM among patients with PSA levels less than the median of 26 ng/mL (sub-distribution hazard ratio, 0.50; 95% confidence interval [CI] 0.28-0.88; P = .02) but not greater than the median (hazard ratio [HR], 1.15; 95% CI 0.67-1.96; P = .62) (P = .038 for interaction). ADT-RT was also associated with improved ACM among patients with PSA levels less than the median (HR, 0.38; 95% CI 0.25-0.57; P < .001) but not greater than the median (HR, 0.91; 95% CI 0.60-1.38; P = .66) (P = .004 for interaction).Conclusions: Definitive treatment with ADT-RT is associated with improved PCSM and ACM among patients with clinically node-positive prostate cancer and lower baseline PSA levels. Patients with clinically node-positive disease appear to be a heterogeneous cohort, with a subset who may achieve long-term survival with combined RT and ADT. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results